1. Home
  2. BRLT vs SCYX Comparison

BRLT vs SCYX Comparison

Compare BRLT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.54

Market Cap

36.6M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.80

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRLT
SCYX
Founded
2005
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6M
32.6M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BRLT
SCYX
Price
$1.54
$0.80
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$2.00
$3.00
AVG Volume (30 Days)
74.0K
336.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$422,161,000.00
$257,000.00
Revenue This Year
$5.92
$170.77
Revenue Next Year
$4.06
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$0.57
52 Week High
$3.10
$1.29

Technical Indicators

Market Signals
Indicator
BRLT
SCYX
Relative Strength Index (RSI) 47.43 57.56
Support Level $1.34 $0.69
Resistance Level $1.65 $0.88
Average True Range (ATR) 0.10 0.06
MACD 0.01 -0.00
Stochastic Oscillator 73.68 69.63

Price Performance

Historical Comparison
BRLT
SCYX

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: